FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Addr	ress of Reporting Pers OBERT N	son [*]	2. Issuer Name and Ticker or Trading Symbol SYNTA PHARMACEUTICALS CORP [SNTA]		tionship of Reporting Pe all applicable) Director	10% Owner			
(Last) (First) C/O SYNTA PHARMACEUTIC		(Middle) LS CORP.	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2009		Officer (give title below)	Other (specify below)			
45 HARTWELL AVENUE			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)				X	Form filed by One Rep	oorting Person			
LEXINGTON	MA	02421			Form filed by More tha Person	n One Reporting			
(City) (State) (Zip)		(Zip)							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									

able I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock	07/01/2009		A		8,403(1)	A	\$0 ⁽¹⁾	364,677	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

(0.3.) parts, carrier, opriorie, corrections of															
1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Year)		4. Transact Code (In 8)		5. 6. Date Exercisable and Number of Expiration Date (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		ate	nd 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director Stock Option (Right to Buy)	\$2.38	07/01/2009		A		5,500		(2)	07/01/2019	Common Stock	5,500	\$0	5,500	D	

Explanation of Responses:

1. Represents a restricted stock grant subject to the Issuer's lapsing forfeiture right, which lapses as to 25% of the shares on each of September 30, 2009, December 31, 2009, March 31, 2010 and June 30, 2010, provided the Reporting Person continues to serve as a director of the Issuer on such date.

2. The option vests as to 25% of the shares on each of September 30, 2009, December 31, 2009, March 31, 2010 and June 30, 2010, provided the Reporting Person continues to serve as a director of the Issuer on such date.

/s/ Ann Margaret Eames, Attorney-in-Fact

07/06/2009

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.